Ferric Carboxymaltose for the Treatment of Anemia during Antenatal and Postpartum Period: Expert Opinion

Malhotra, Narendra; Malhotra, Jaideep; Gupte, Sanjay; Mahapatra, PC; Malhotra, Neharika; Tandulwadkar, Sunita; Garg, Ruchika; Gopinath, P. M.; Bapat, Kawita; Gupta, Mahesh; Bhat, Vidya V; Pandit, Suchitra; Swami, Onkar C; Shenoy, Sheela; Boruah, Arun M; Shah, Milind R

doi:10.5005/jp-journals-10006-2026

Cited by 2 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 There was an improved sense of well-being among the patients over a period of time. 16,17 conclusIon The present study documented that administration of FCM in moderate-to-severe anemic pregnant women resulted in a rapid and sequential rise in hemoglobin. Single large dose FCM administration offers better compliance than other IV and oral preparations in moderate-to-severe anemic patients.…”

Section: Discussionsupporting

confidence: 54%

Effectiveness of Single-dose Ferric Carboxymaltose in Enhancing Hemoglobin Levels in Pregnant Women with Moderate-to-Severe Iron-deficiency Anemia

Badkur,

Agarwal,

Wadhwani

et al. 2023

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Background: Anemia contributes to increased pregnancy-associated morbidity and mortality; hence warranting rapid correction. Parenteral ferric carboxymaltose (FCM) has FDA and DCGI approval for use in pregnancy-linked iron-deficiency anemia, with minimal and nonserious side effects. Ferric carboxymaltose is given as a single-dose administration, requiring lesser hospital visits and costs. FCM has been accepted for clinical use in the Indian population. However, there is limited evidence about its use for moderate or severe anemia among antenatal women. This study aims to analyze the efficacy and safety of single-dose intravenous ferric carboxy maltose among anemic pregnant females. Methods: Prospective observational study comprising 150 iron-deficiency anemic pregnant women between 16 and 32 weeks of gestation with hemoglobin between 5 and 9 gm/dL. Single dose of FCM (dose calculated by Ganzoni's formula) was administered and treatment effectiveness was assessed by serial hemoglobin measurement at 2 weeks and 6 weeks after administration of FCM and then at the time of delivery. Safety was determined by analysis of adverse drug reactions and biochemical tests at the aforesaid time intervals. Results: The mean rise in hemoglobin at 2 weeks was 1.35 gm/dL, at 6 weeks was 3.08 gm/dL and at delivery was 4.80 gm/dL (p < 0.001). No serious adverse effects were found. Conclusions: The present study bolsters clinical use of intravenous FCM in anemic pregnant females in view of its efficacy and safety. Low-risk single dose dispensation and subsequent upsurge in hemoglobin levels should place FCM as a preferred alternative in moderate-to-severe anemia management during pregnancy.

show abstract

Section: Discussionsupporting

confidence: 54%

Effectiveness of Single-dose Ferric Carboxymaltose in Enhancing Hemoglobin Levels in Pregnant Women with Moderate-to-Severe Iron-deficiency Anemia

Badkur,

Agarwal,

Wadhwani

et al. 2023

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…Ferric carboxymaltose for the treatment of anemia during Antenatal and Postpartum period: expert opinion by PC Mahapatra, Sanjay Gupte. 19 FCM should be used within 12-32 weeks of pregnancy and in postpartum period after 24 hours of delivery. Within 6 weeks of FCM treatment, there was rise in Hb by nearly 3-4 gm/dl with a significant rise in ferritin and replenishment of iron stores.…”

Section: Discussionmentioning

confidence: 99%

Role of ferric carboxymaltose in battle with anemia among north Indian pregnant women

Verma,

Bharati,

Jain

et al. 2023

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Anemia among pregnant women is a serious global health concern. Anemia is a major hematological, nutritional deficiency but still a manageable health problem among the pregnant women and very common in developing countries like India in under privileged population. Increased morbidity and mortality is seen in pregnant women and their foetuses suffering from anemia. Aim of this study was to study safety and efficacy of injection ferric carboxymaltose in pregnant women with iron deficiency anemia. Methods: This is a Prospective interventional comparative randomized study carried among antenatal women in the Department of Obstetrics and Gynaecology, S. N. Medical College, Agra from (May 2021-October 2022), comprised of 200 pregnant women divided into two groups. Group A-100 antenatal women were transfused with iron sucrose (IS), Group B-100 antenatal women were transfused with ferric carboxymaltose (FCM). Results: In FCM group after 3 weeks of post transfusion hemoglobin level was 10.5±0.44 and in iron sucrose group it was 9.9±0.59 (p=0.0001). 6 week post transfusion hemoglobin level in FCM group was 11.37±0.62 and in iron sucrose group it was 10.45±0.59 (p=0.0001). Average rise in hemoglobin in FCM group after 3 week post transfusion was 2.9±0.02 and after 6 week it was 3.77±0.16. In iron sucrose group at 3 week it was 2.1±0.06 and at 6 week it was 2.65±0.04. The average rise in hemoglobin level was greater among patients of FCM compared to Iron sucrose group. Conclusions: Ferric carboxymaltose was safe and more effective in treatment of iron deficiency anaemia in pregnant women as compared to iron sucrose with lesser side effect and better patient compliance.

show abstract

Ferric Carboxymaltose for the Treatment of Anemia during Antenatal and Postpartum Period: Expert Opinion

Cited by 2 publications

References 56 publications

Effectiveness of Single-dose Ferric Carboxymaltose in Enhancing Hemoglobin Levels in Pregnant Women with Moderate-to-Severe Iron-deficiency Anemia

Effectiveness of Single-dose Ferric Carboxymaltose in Enhancing Hemoglobin Levels in Pregnant Women with Moderate-to-Severe Iron-deficiency Anemia

Role of ferric carboxymaltose in battle with anemia among north Indian pregnant women

Contact Info

Product

Resources

About